0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Clinical Trials |

Retinal Effects of 6 Months of Daily Use of Tadalafil or Sildenafil

William H. Cordell, MD; Raj K. Maturi, MD; Timothy M. Costigan, PhD; Michael F. Marmor, MD; Richard G. Weleber, MD; Stuart G. Coupland, PhD; Ronald P. Danis, MD; John W. McGettigan Jr, MD; Andrew N. Antoszyk, MD; Suzanne Klise, BS; Gregory D. Sides, MD ; ERG Testing During Chronic PDE5 Inhibitor Administration (ERG-PDE5i) Consortium
Arch Ophthalmol. 2009;127(4):367-373. doi:10.1001/archophthalmol.2009.36.
Text Size: A A A
Published online

Objective  To assess changes in electroretinography (ERG) and other retinal function parameters during 6 months of daily use of tadalafil, sildenafil citrate, or placebo.

Methods  Subjects were randomized to use of a placebo (n = 82), 5 mg of tadalafil (n = 85), or 50 mg of sildenafil (n = 77) daily for 6 months. Electroretinographs were recorded using the International Society for Clinical Electrophysiology of Vision (ISCEV) protocol and standardized ERG equipment at all 15 study sites. Other tests of ocular anatomy and visual function were performed at each assessment.

Main Outcome Measures  The primary outcome was the average mean change for both eyes from baseline to endpoint in ERG b-wave amplitude using dark-adapted combined standard response to a bright ISCEV standard flash. Secondary endpoints were other ERG parameter changes, visual acuity, number of errors in color discrimination testing, mean deviation in automated visual field testing, and intraocular pressure (IOP).

Results  No significant differences were found between treatment/placebo groups for the primary outcome, most other ERG variables, visual function, IOP, or anatomic assessments. The medications were well tolerated.

Conclusions  No abnormalities in ERG or visual function and no treatment-related findings suggestive of drug toxicity are associated with daily administration of tadalafil or sildenafil for 6 months.

Application to Clinical Practice  Assessed visual safety of tadalafil/sildenafil administered daily over a prolonged period.

Trial Registration  clinicaltrials.gov Identifier: NCT00333281

Figures in this Article

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

Figures

Place holder to copy figure label and caption
Figure 1.

Study design. ERG indicates electroretinography. Comprehensive ophthalmologic examination included ERG unless otherwise noted.

Graphic Jump Location
Place holder to copy figure label and caption
Figure 2.

Subject disposition and derivation of the 2 data analysis sets. Numbers in parentheses and dotted lines represent discontinuations and/or deletions from the 2 analysis sets. Of the 244 randomized subjects, 194 completed 6 months of treatment. Reasons for discontinuation prior to completing 6 months of drug therapy are as follows by group: 9 placebo, 5 tadalafil, and 2 sildenafil subjects had a personal conflict or other subject decision; 2 placebo, 1 tadalafil, and 0 sildenafil subjects had protocol violations; 5 placebo, 3 tadalafil, and 4 sildenafil subjects had entry criterion violations; 2 placebo, 2 tadalafil, and 3 sildenafil subjects could not be contacted; 2 placebo, 1 tadalafil, and 6 sildenafil subjects had an adverse event; 1 tadalafil subject was given the incorrect drug; and 2 sildenafil subjects were unmasked.

Graphic Jump Location

Tables

References

Correspondence

CME


You need to register in order to view this quiz.
NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).
Submit a Comment

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Topics
PubMed Articles
Jobs
brightcove.createExperiences();